Flexion Therapeutics Inc (FLXN) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. cut its holdings in Flexion Therapeutics Inc (NASDAQ:FLXN) by 1.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 164,400 shares of the specialty pharmaceutical company’s stock after selling 2,950 shares during the quarter. JPMorgan Chase & Co. owned about 0.44% of Flexion Therapeutics worth $3,927,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in FLXN. Fiduciary Trust Co. acquired a new position in shares of Flexion Therapeutics in the second quarter valued at about $101,000. Advisor Group Inc. increased its holdings in shares of Flexion Therapeutics by 205.9% in the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 3,500 shares during the period. SG Americas Securities LLC acquired a new position in shares of Flexion Therapeutics in the third quarter valued at about $135,000. IFP Advisors Inc increased its holdings in shares of Flexion Therapeutics by 58.1% in the third quarter. IFP Advisors Inc now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $194,000 after purchasing an additional 2,950 shares during the period. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Flexion Therapeutics in the third quarter valued at about $235,000. Institutional investors own 72.78% of the company’s stock.

A number of research analysts have recently weighed in on FLXN shares. Janney Montgomery Scott increased their price objective on Flexion Therapeutics to $570.00 and gave the company a “fair value” rating in a report on Tuesday, October 10th. Wells Fargo & Co set a $39.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a report on Friday, October 6th. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price objective on shares of Flexion Therapeutics in a report on Sunday, September 17th. Zacks Investment Research lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Finally, Royal Bank of Canada set a $44.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a report on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $106.25.

In related news, insider Michael D. Clayman bought 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The shares were purchased at an average cost of $23.60 per share, with a total value of $118,000.00. Following the completion of the acquisition, the insider now directly owns 35,395 shares in the company, valued at $835,322. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Neil Bodick bought 2,700 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The shares were bought at an average cost of $24.49 per share, for a total transaction of $66,123.00. Following the completion of the acquisition, the insider now owns 64,605 shares of the company’s stock, valued at $1,582,176.45. The disclosure for this purchase can be found here. 15.98% of the stock is owned by company insiders.

Shares of Flexion Therapeutics Inc (FLXN) opened at $26.43 on Wednesday. The company has a market capitalization of $992.20, a PE ratio of -7.51 and a beta of 1.15. Flexion Therapeutics Inc has a 1-year low of $16.51 and a 1-year high of $32.25. The company has a current ratio of 12.93, a quick ratio of 12.93 and a debt-to-equity ratio of 0.87.

COPYRIGHT VIOLATION NOTICE: This report was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2018/01/03/flexion-therapeutics-inc-flxn-shares-sold-by-jpmorgan-chase-co.html.

Flexion Therapeutics Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply